Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain

OBJECTIVE: To evaluate the cost-effectiveness of obinutuzumab in combination with chlorambucil (GClb) versus rituximab plus chlorambucil (RClb) in the treatment of adults with previously untreated chronic lymphocytic leukemia (CLL) and with comorbidities that make them unsuitable for full-dose fluda...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clinicoecon Outcomes Res
Main Authors: Casado, Luis Felipe, Burgos, Amparo, González-Haba, Eva, Loscertales, Javier, Krivasi, Tania, Orofino, Javier, Rubio-Terres, Carlos, Rubio-Rodríguez, Darío
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5036824/
https://ncbi.nlm.nih.gov/pubmed/27703384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S114524
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados